Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) and CervoMed (NASDAQ:CRVO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
Institutional and Insider Ownership
75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 35.8% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Cyclerion Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, CervoMed has a beta of -0.75, meaning that its share price is 175% less volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cyclerion Therapeutics | $2.07 million | 7.89 | -$3.53 million | ($1.66) | -2.10 |
| CervoMed | $4.01 million | 11.10 | -$26.97 million | ($3.22) | -0.91 |
Cyclerion Therapeutics has higher earnings, but lower revenue than CervoMed. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cyclerion Therapeutics and CervoMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cyclerion Therapeutics | -170.11% | -87.96% | -74.86% |
| CervoMed | N/A | -156.02% | -128.34% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Cyclerion Therapeutics and CervoMed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cyclerion Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| CervoMed | 1 | 1 | 4 | 1 | 2.71 |
CervoMed has a consensus price target of $21.00, indicating a potential upside of 613.32%. Given CervoMed’s stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Cyclerion Therapeutics.
Summary
CervoMed beats Cyclerion Therapeutics on 9 of the 15 factors compared between the two stocks.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
About CervoMed
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
